439117-38-1

Basic information

• Product Name: METHYL 5-CHLORO-2-CYANOBENZOATE
• Synonyms: METHYL 5-CHLORO-2-CYANOBENZOATE;BENZOIC ACID, 5-CHLORO-2-CYANO-, METHYL ESTER;4-Chloro-2-methoxycarbonylbenzonitrile
• CAS NO: 439117-38-1
• Molecular Formula: C₉H₆ClNO₂
• Molecular Weight: 195.6
• Mol File: 439117-38-1.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 328.1°C at 760 mmHg
• Flash Point: 152.2°C
• Appearance: /
• Density: 1.32g/cm³
• Vapor Pressure: 0.000194mmHg at 25°C
• Refractive Index: 1.554
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: METHYL 5-CHLORO-2-CYANOBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 5-CHLORO-2-CYANOBENZOATE(439117-38-1)
• EPA Substance Registry System: METHYL 5-CHLORO-2-CYANOBENZOATE(439117-38-1)

Safety Data

• Hazardous Substances Data: 439117-38-1(Hazardous Substances Data)

Usage

General Description

Methyl 5-chloro-2-cyanobenzoate is a chemical compound with the molecular formula C9H6ClNO2. It is a colorless to pale yellow solid that is commonly used as an intermediate in the production of pharmaceuticals and agrochemicals. It is also known for its strong odor and is considered to be toxic when inhaled, ingested, or in contact with the skin. METHYL 5-CHLORO-2-CYANOBENZOATE is primarily used as a building block in the synthesis of various organic compounds and is often employed in chemical research and manufacturing processes.

InChI:InChI=1/C9H6ClNO2/c1-13-9(12)8-4-7(10)3-2-6(8)5-11/h2-4H,1H3

Upstream product

• 557-21-1 dicyanozinc 
• 494210-98-9 methyl 5-chloro-2-[((trifluoromethyl)sulfonyl)oxy]benzoate 
• 544-92-3 copper(I) cyanide 
• 14221-01-3 tetrakis(triphenylphosphine) palladium⁽⁰⁾ 
• 27007-53-0 methyl-2-bromo-5-chlorobenzoate 
• 557-21-1 zinc(II) cyanide 
• 56961-26-3 2-bromo-3-chlorobenzoic acid 
• 4068-78-4 methyl 5-chloro-2-hydroxybenzoate 
• 21739-93-5 2-bromo-5-chlorobenzoic acid 

Downstream Products

• 58083-59-3 6-chloroisoindolin-1-one 
• 928754-18-1 (4-chloro-2-chloromethyl-benzyl)-carbamic acid tert-butyl ester 
• 439117-43-8 N-fluorenylmethoxycarbonyl-L-prolyl-2-(tert-butyloxycarbonylaminomethyl)-5-chlorobenzylamide 
• 439117-99-4 1-(N (fluorenylmethoxycarbonyl)-azetidin-2S-yl-carbonylaminomethyl)-2-(tert-butyloxycarbonylaminomethyl)-5-chlorobenzene 
• 439117-46-1 [4-Chloro-2-({[(S)-1-((R)-2-cyclohexyl-2-hydroxy-acetyl)-pyrrolidine-2-carbonyl]-amino}-methyl)-benzyl]-carbamic acid tert-butyl ester 
• 486394-58-5 [4-Chloro-2-({[(S)-1-((R)-3-cyclopropyl-2-hydroxy-3-methyl-butyryl)-azetidine-2-carbonyl]-amino}-methyl)-benzyl]-carbamic acid tert-butyl ester 
• 439117-51-8 [4-Chloro-2-({[(S)-1-((R)-2-hydroxy-2-phenyl-propionyl)-pyrrolidine-2-carbonyl]-amino}-methyl)-benzyl]-carbamic acid tert-butyl ester 
• 439117-45-0 [4-Chloro-2-({[(S)-1-((R)-2-hydroxy-3,3-dimethyl-butyryl)-pyrrolidine-2-carbonyl]-amino}-methyl)-benzyl]-carbamic acid tert-butyl ester 
• 439117-50-7 [4-Chloro-2-({[(S)-1-((R)-2-hydroxy-3-methyl-butyryl)-pyrrolidine-2-carbonyl]-amino}-methyl)-benzyl]-carbamic acid tert-butyl ester 
• 486394-64-3 [4-Chloro-2-({[(S)-1-((R)-2-hydroxy-3,3-dimethyl-butyryl)-azetidine-2-carbonyl]-amino}-methyl)-benzyl]-carbamic acid tert-butyl ester 
• 439116-15-1 2-(tert-butyloxycarbonylaminomethyl)-5-chlorobenzylamine 
• 439117-41-6 1-azidomethyl-2-(tert-butyloxycarbonylaminomethyl)-5-chlorobenzene 
• 439117-40-5 tert-butyl 4-chloro-2-(hydroxymethyl)benzylcarbamate 

Relevant articles and documents

HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS

The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.

THERAPEUTIC USE OF ARYL AMINO ACID DERIVATIVES

The compounds of formula (I) are useful in the treatment of faintness attacks, hypokinesia, cranial disorders, neurodegenerative disorders, depression, anxiety, panic, neuropathic pain, neuropathological disorders and sleep disorders. Processes for the preparation of the final products and intermediates useful in the process are included. Pharmaceutical compositions containing one or more of the compounds are also included.

Low molecular weight thrombin inhibitors with excellent potency, metabolic stability, and oral bioavailability

Modification of lead compound 1 by reducing lipophilicity in the P3 group produced a series of low molecular weight thrombin inhibitors with excellent potency in functional assays, metabolic stability, and oral bioavailability. These modifications led to